The trademark mREZVI was filed by ModernaTX, Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on January 24, 2023, and received one opposition filed on April 24, 2023 by GlaxoSmithKline Biologicals S.A. on Likelihood of confusion. the opponent was represented by HOYNG ROKH MONEGIER PARTNERSCHAFTSGESELLSCHAFT VON RECHTSANWÄLTEN, ADVOCATEN UND AVOCATS À LA COUR MBB and proceedings were handled in German, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued April 24, 2023
The application was filed in English, and English was also language of all opposition proceedings (German was selected as the second language).